1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. ERYTHROPOIETIN DRUGS MARKET, BY TYPE
5.1. Introduction
5.2. Biologics
5.3. Biosimilars
6. ERYTHROPOIETIN DRUGS MARKET, BY PRODUCT
6.1. Introduction
6.2. Erythropoietin
6.3. Darbepoetin-alfa
7. ERYTHROPOIETIN DRUGS MARKET, BY APPLICATION
7.1. Introduction
7.2. Cancer
7.3. Renal Diseases
7.4. Neurology
7.5. Others
8. ERYTHROPOIETIN DRUGS MARKET, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. The Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
10. COMPANY PROFILES
10.1. Mayo Clinic
10.2. Weefsel Pharma
10.3. Trumac Healthcare
10.4. Incepta Pharmaceuticals Ltd.
10.5. FosunPharma
10.6. Rewine Pharmaceuticals
10.7. Kyowa Kirin
10.8. Mircera
10.9. ACRO Biosystems
10.10. Fierce Pharma